pSivida Limited (PSDV) Says RetisertTM Drug Implant Receives Product Specific Bill Code and Medicare Reimbursement Rate
More News related to BOL
- Bausch & Lomb Unveils FogShield Sport(TM), an Anti-Fog Treatment for Sports Goggles That Works
- Boliden: Interim Report, January - September 2009
- Center for Patient Insights Web Site Goes Live
- Pierre Heeroma - New Director Group Strategy and Business Development at Boliden
- Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
More News related to PSDV
- pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information
- pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer
- pSivida Announces Last Patient in Phase III Iluvien(R) Trial Completes 2 Year Follow-Up Visit
- pSivida (PSDV) Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study
- pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien(R) Study
More News related to Corporate News
- S&P Raises Red Hat's (RHT) Corporate Credit Rating to 'BB+'
- Hemispherx (HEB) Shares Tumble Amid Class Action Lawsuit by Shareholders
- Sypris Solutions (SYPR) Sibsidiary Awarded $200M 5-Year IDIQ Contract from U.S. DoD to Replace KYK-13
- Lockheed Martin (LMT) Awarded 12-Month Contract from DARPA for Next-Gen MDA Technology Development
- Ford Europe (F) Rolls To Higher Sales and Market Share in October
pSivida Limited (NASDAQ: PSDV) announced that Retisert, developed jointly by pSivida and Bausch & Lomb (NYSE: BOL), has been allocated a product specific J-Code by the Centers for Medicare and Medicaid Services (CMS) in the United States.
The RetisertTM implant was approved as a single indication orphan drug by the United States Food and Drug Administration for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening inflammatory disease and a major cause of blindness. RetisertTM is surgically placed into the back of the eye and releases the steroid, fluocinolone acetonide at a constant rate over a period of up to 30 months. Marketed in the United States by Bausch & Lomb, pSivida receives royalties on sales.
Related Categories
Corporate NewsStocks Mentioned
+0.00
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
